These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 28956332)

  • 41. Genetic Understanding of Stroke Treatment: Potential Role for Phosphodiesterase Inhibitors.
    Munshi A; Das S
    Adv Neurobiol; 2017; 17():445-461. PubMed ID: 28956342
    [TBL] [Abstract][Full Text] [Related]  

  • 42. PDE3 Inhibitors Repurposed as Treatments for Age-Related Cognitive Impairment.
    Yanai S; Endo S
    Mol Neurobiol; 2019 Jun; 56(6):4306-4316. PubMed ID: 30311144
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phosphodiesterase regulation of nitric oxide signaling.
    Kass DA; Takimoto E; Nagayama T; Champion HC
    Cardiovasc Res; 2007 Jul; 75(2):303-14. PubMed ID: 17467673
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chronic phosphodiesterase type 2 inhibition improves memory in the APPswe/PS1dE9 mouse model of Alzheimer's disease.
    Sierksma AS; Rutten K; Sydlik S; Rostamian S; Steinbusch HW; van den Hove DL; Prickaerts J
    Neuropharmacology; 2013 Jan; 64():124-36. PubMed ID: 22771768
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phosphodiesterase inhibitors enhance object memory independent of cerebral blood flow and glucose utilization in rats.
    Rutten K; Van Donkelaar EL; Ferrington L; Blokland A; Bollen E; Steinbusch HW; Kelly PA; Prickaerts JH
    Neuropsychopharmacology; 2009 Jul; 34(8):1914-25. PubMed ID: 19262466
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Characterization of renal ecto-phosphodiesterase.
    Jackson EK; Ren J; Zacharia LC; Mi Z
    J Pharmacol Exp Ther; 2007 May; 321(2):810-5. PubMed ID: 17308037
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors.
    Verghese MW; McConnell RT; Strickland AB; Gooding RC; Stimpson SA; Yarnall DP; Taylor JD; Furdon PJ
    J Pharmacol Exp Ther; 1995 Mar; 272(3):1313-20. PubMed ID: 7891349
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cyclic nucleotide-mediated regulation of vascular smooth muscle cell cyclic nucleotide phosphodiesterase activity. Selective effect of cyclic AMP.
    Maurice DH
    Cell Biochem Biophys; 1998; 29(1-2):35-47. PubMed ID: 9631237
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Expression and function of phosphodiesterases in nitrofen-induced congenital diaphragmatic hernia in rats.
    van der Horst IW; Morgan B; Eaton F; Reiss I; Tibboel D; Thébaud B
    Pediatr Pulmonol; 2010 Apr; 45(4):320-5. PubMed ID: 20196107
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Characterization of cyclic nucleotide phosphodiesterases with cyclic GMP analogs: topology of the catalytic domains.
    Beltman J; Becker DE; Butt E; Jensen GS; Rybalkin SD; Jastorff B; Beavo JA
    Mol Pharmacol; 1995 Feb; 47(2):330-9. PubMed ID: 7870041
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Phosphodiesterase regulation of cardiovascular functions].
    Li L; He Q; Gao YS
    Sheng Li Ke Xue Jin Zhan; 2010 Apr; 41(2):100-6. PubMed ID: 21416994
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Modulating nitric oxide signaling in the CNS for Alzheimer's disease therapy.
    Zhihui Q
    Future Med Chem; 2013 Aug; 5(12):1451-68. PubMed ID: 23919554
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents.
    Lugnier C
    Pharmacol Ther; 2006 Mar; 109(3):366-98. PubMed ID: 16102838
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phosphodiesterase inhibitors in psychiatric disorders.
    Sadeghi MA; Nassireslami E; Yousefi Zoshk M; Hosseini Y; Abbasian K; Chamanara M
    Psychopharmacology (Berl); 2023 Jun; 240(6):1201-1219. PubMed ID: 37060470
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phosphodiesterases and cyclic GMP regulation in heart muscle.
    Lee DI; Kass DA
    Physiology (Bethesda); 2012 Aug; 27(4):248-58. PubMed ID: 22875455
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS.
    Andersson KE; Uckert S; Stief C; Hedlund P
    Neurourol Urodyn; 2007 Oct; 26(6 Suppl):928-33. PubMed ID: 17806124
    [TBL] [Abstract][Full Text] [Related]  

  • 57. PDE4 and PDE5 regulate cyclic nucleotides relaxing effects in human umbilical arteries.
    Santos-Silva AJ; Cairrão E; Morgado M; Alvarez E; Verde I
    Eur J Pharmacol; 2008 Mar; 582(1-3):102-9. PubMed ID: 18234184
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phosphodiesterase 1: A Unique Drug Target for Degenerative Diseases and Cognitive Dysfunction.
    Wennogle LP; Hoxie H; Peng Y; Hendrick JP
    Adv Neurobiol; 2017; 17():349-384. PubMed ID: 28956339
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phosphodiesterase isoenzymes in the human urethra: a molecular biology and functional study.
    Kedia GT; Oelke M; Sonnenberg JE; Sohn M; Bannowsky A; Kuczyk MA; Ückert S
    Eur J Pharmacol; 2014 Oct; 741():330-5. PubMed ID: 25160741
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cyclic AMP-specific and cyclic GMP-specific phosphodiesterase isoenzymes in human cavernous arteries--immunohistochemical distribution and functional significance.
    Waldkirch E; Uckert S; Yildirim H; Sohn M; Jonas U; Stief CG; Andersson KE; Hedlund P
    World J Urol; 2005 Dec; 23(6):405-10. PubMed ID: 16292559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.